DONATE
GET INVOLVED
Drug Development Pipeline
Tobramycin Inhaled Powder (TOBI® Podhaler™)
Status
To PatientsTherapeutic Approach
Anti-Infective
The TOBI® Podhaler™ is the powder form of the inhaled antibiotic tobramycin and is used to treat people with CF who have Pseudomonas aeruginosa. It is taken with an inhaler, making it a convenient alternative to TOBI®, which must be taken using a nebulizer.
Status
The TOBI Podhaler received FDA approval in March 2013 for people with CF.
Sponsor
The program is sponsored by Novartis Pharmaceuticals and supported by the Cystic Fibrosis Foundation. The trial was conducted within the Therapeutics Development Network.
Recent Tobramycin Inhaled Powder (TOBI® Podhaler™) Studies
-
Completed with Results
Tobramycin Inhalation Powder Compared to TOBI in People with CF (CTBM100C2302)
Latest News on Tobramycin Inhaled Powder
-
FDA Approves New Powder Form of CF Drug TOBI®
March 25, 2013
Learn moreThe U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).
-
FDA Advisory Committee Backs New Form of CF Drug
September 07, 2012
Learn moreA U.S. Food and Drug Administration outside advisory panel has backed a new form of the CF drug TOBI® (tobramycin solution for inhalation).
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More